# Clinical Trials Data KRAS - Document 20

# Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT00964457

"eligibilityCriteria": "Inclusion Criteria:\n\n\* advanced rectum cancer\n\nExclusion Criteria:\n\n\* prior radiation",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
This trial information doesn't mention KRAS mutation status as either an inclusion or exclusion criterion. Therefore, having a KRAS mutation \*doesn't automatically disqualify\* the patient. They \*could\* be eligible if they meet the other criteria (advanced rectum cancer and no prior radiation) and are within the age range. However, more information would be needed to determine definitive eligibility.